Retatrutide trials and reported results
Retatrutide is being studied for obesity and related conditions. It is a different molecule from semaglutide: retatrutide activates GIP, GLP-1, and glucagon receptors, three proteins that receive hormone signals. The number of receptors does not by itself establish which treatment would suit a person.
As of November 3, 2026, retatrutide had no FDA-approved use. Published phase 3 trials now add to the earlier phase 2 evidence, but publication and regulatory approval are separate steps. FDA's information on unapproved GLP-1 drugs identifies retatrutide as an ingredient without an approved drug product.
The earlier obesity trial
The 2023 phase 2 study enrolled 338 adults with obesity, or overweight with a related condition. Over 48 weeks, the highest retatrutide study group had average weight loss of 24.2%, compared with 2.1% for placebo. This was a randomized trial: participants were assigned to study groups by chance, helping researchers compare their outcomes.
The result was substantial, but it came from a defined population over a defined period. It did not establish long-term protection from heart attacks, kidney failure, or other serious events. Nor did it test every preparation offered under retatrutide's name outside the study.
Reading the phase 3 results
The published TRIUMPH-1 trial studied 2,339 adults without diabetes for 80 weeks. In the analysis accounting for treatment changes, average weight loss was 25.0% in the highest retatrutide group and 3.9% with placebo. Lilly funded the trial, which was published in 2026.
The TRIUMPH-2 publication addressed adults with overweight or obesity and type 2 diabetes. It randomized 1,152 participants and followed them for 80 weeks. The corresponding treatment-regimen analysis found average weight loss of 18.8% in the highest retatrutide group and 5.1% with placebo. This trial was also funded by Lilly.
The diabetes and non-diabetes populations are not interchangeable. Their results belong beside their own placebo groups, rather than in a table that treats every percentage as an equally matched contest. Differences in background medicines and health conditions can affect interpretation.
Published estimates can also differ because the statistical questions differ. An analysis that accounts for treatment interruptions asks a different question from one focused on outcomes under continued treatment. Quoting a larger headline without identifying that distinction can leave a misleading impression. The figures above stay within one stated analysis for each trial.
Unwanted effects and unanswered questions
Digestive problems were common in the phase 2 research, including nausea, vomiting, diarrhea, and constipation. The obesity trial also found heart-rate increases that tended to be larger in higher study groups. They peaked around week 24 and then declined. That pattern is a safety observation; it does not determine cardiovascular risk over several years.
TRIUMPH-2 reported altered or unpleasant skin sensations, known as dysesthesia. These occurred in roughly 4–7% of retatrutide participants and about 1% of placebo participants. The paper also reported treatment discontinuations. A large average weight change remains only one part of the assessment when unwanted effects prevent some participants from continuing.
Retatrutide has no FDA-approved prescribing label. It would be inaccurate to fill that gap by copying another drug's contraindications or pregnancy instructions. Mechanistic similarities can suggest research questions, but they do not create a complete, reviewed safety profile for a different molecule.
Research evidence and access
A clinical trial provides specified medicines, eligibility checks, follow-up, and a process for recording adverse events. A commercial description using the same ingredient name does not establish that these safeguards or the same preparation are present. A research-use label also does not make a product an approved human medicine.
This page reports study findings without turning trial groups into a personal schedule. It gives no preparation, mixing, or dose instructions. Questions about a study result can be taken to a clinician alongside the publication, including which participants were excluded and how many stopped treatment.
For comparison with semaglutide, the useful question is which outcomes were measured in comparable people, with comparable follow-up. The research comparison keeps clinical events, weight change, and laboratory findings distinct. The source list retains the publications needed to examine each claim in context.